TruScreen Group Limited Stock price

Equities

TRU

NZTRUE0001S7

Advanced Medical Equipment & Technology

End-of-day quote New Zealand S.E. 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
0.022 NZD 0.00% Intraday chart for TruScreen Group Limited +10.00% -4.35%
Sales 2022 2.55M 1.52M Sales 2023 2.08M 1.24M Capitalization 12.08M 7.2M
Net income 2022 -7M -4.17M Net income 2023 -2M -1.19M EV / Sales 2022 9.01 x
Net cash position 2022 2.8M 1.67M Net cash position 2023 2.16M 1.29M EV / Sales 2023 4.77 x
P/E ratio 2022
-3.26 x
P/E ratio 2023
-4.4 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 87.32%
More Fundamentals * Assessed data
Dynamic Chart
1 week+10.00%
3 months-8.33%
6 months-15.38%
Current year-4.35%
More quotes
1 week
0.02
Extreme 0.02
0.02
1 month
0.02
Extreme 0.019
0.02
Current year
0.02
Extreme 0.019
0.03
1 year
0.02
Extreme 0.019
0.04
3 years
0.02
Extreme 0.019
0.11
5 years
0.02
Extreme 0.019
0.19
10 years
0.02
Extreme 0.019
0.32
More quotes
Date Price Change Volume
24-03-27 0.022 0.00% 59,415
24-03-26 0.022 -8.33% 526,440
24-03-25 0.024 +20.00% 680,953
24-03-22 0.02 0.00% 178,190
24-03-21 0.02 0.00% 346,359

End-of-day quote New Zealand S.E., March 26, 2024

More quotes
Truscreen Group Limited is a New Zealand-based medical device company. The Company is engaged in the development of an artificial intelligence (AI)-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. The Company’s cervical screening technology resolves ongoing issues with cytology, including failed samples, poor patient follow-up, patient discomfort, and the need for supporting laboratory infrastructure. The TruScreen device uses opto-electrical technology to evaluate the tissue of the cervix. The TruScreen device consists of a disposable Single Use Sensor (SUS), a Handheld Device (HHD), and an Intelligent Cradle (IC) which works together to detect and identify cancerous and precancerous changes to the cervix. It also resolves the problems associated with human papillomavirus (HPV) testing, which tests for the much more prevalent HPV virus.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock TruScreen Group Limited - New Zealand S.E.